The impact of the initial doses may include some gastrointestinal side effects, such as nausea and diarrhea
Likewise, the cardiovascular benefit of efpeglenatide was independent of GFR or the concomitant use of iSGLT-2, suggesting its additive and independent effect from the latter,85 as was also observed in the EXSCEL study.86 A recent meta-analysis of the 8 published cardiovascular safety clinical trials, and which included a total of 60
With those changes in LDL and total cholesterol, retatrutide may assist in lowering the risk of heart disease, which tends to run rampant among individuals with fatty liver and metabolic syndrome
Wegovy Patient Information Leaflet (emc)
Based on phase 2 trial data, early appetite suppression may be noticed within the first two to four weeks of treatment
Retatrutide was developed as a successor compound to dual incretin agonists (such as tirzepatide), adding glucagon receptor agonism to the GLP-1/GIP profile